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AIMS
It has been suggested that sulodexide is able to lower blood pressure (BP). This may be attributed to its ability to restore the
endothelial surface layer (ESL). As ESL perturbation is known to be related to the degree of kidney damage, we investigated
whether albuminuria, reﬂecting ESL status, modiﬁed the BP-lowering potential of sulodexide.
METHODS
A post hoc analysis of the double-blind, randomized, placebo-controlled sulodexide microalbuminuria (Sun-MICRO) and
macroalbuminuria (Sun-MACRO) studies, including 1056 microalbuminuric and 843 macroalbuminuric subjects with type 2 di-
abetes receiving maximal tolerated renin–angiotensin-aldosterone system inhibitor therapy, was carried out. We compared the
effect of placebo and sulodexide on systolic BP (SBP) among albuminuria groups.
RESULTS
Analysis of covariance, including data from both trials, showed that baseline urine albumin-to-creatinine ratio (UACR) was the
only modiﬁer of the SBP response (interaction with treatment P = 0.001). In subjects with an UACR >1000 mg g–1, sulodexide
lowered SBP by 4.6 mmHg [95% conﬁdence interval (CI) 3.6, 5.6; P< 0.001] compared with placebo, whereas a 2.3 mmHg (95%
CI 0.9,3.7; P = 0.001) reduction was seen in subjects with a UACR of 300–1000 mg g–1. Sulodexide did not lower SBP in subjects
with a UACR <300 mg g–1 (0.2 mmHg, 95% CI 0.8, 0.5; P = 0.60). SBP-lowering effects were not accompanied by changes in
body weight.
CONCLUSION
The BP-reducing potency of sulodexide is modiﬁed by the degree of albuminuria in subjects with type 2 diabetes. As ESL status
deteriorates with increasing albuminuria and nephropathy severity, this suggests that ESL restoration may represent a new target
for BP treatment in subjects with diabetic nephropathy.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Sulodexide has been shown to have antihypertensive potency.
• Sulodexide consists of glycosaminoglycans that are known to play an important role in endothelial function and sodium
homeostasis.
• There is a relationship between the volume of the endothelial surface layer and albuminuria.
WHAT THIS STUDY ADDS
• The urine albumin–creatinine ratio is an important modiﬁer of blood pressure responses to sulodexide treatment.
• Sulodexide reduces blood pressure in macroalbuminuric diabetic subjects receiving maximally tolerated renin–
angiotensin-aldosterone system inhibitor therapy.
• The endothelial surface layer, of which the status reﬂected by albuminuria levels, might represent a novel antihyperten-
sive target in diabetes.
Introduction
Approximately one billion people in the world suffer from
hypertension [4]. Despite effective antihypertensive
treatment, half of the patients with hypertension have an
uncontrolled blood pressure (BP) [5, 6], which has been
shown to increase cardiovascular risk considerably [7]. This
number may be even higher in patients with diabetes, kidney
disease or both. We therefore need new therapeutic inven-
tions to improve BP control in these patients.
In this context, the endothelial surface layer (ESL) is of
interest. The ESL is a dynamic layer that covers the inner
surface of blood vessels throughout the body. The main
constituents of the ESL are proteoglycans with attached
glycosaminoglycans, glycoproteins and soluble proteins. The
ESL has been shown to possess many vasoprotective properties
as it improves endothelial barrier function, prevents leucocyte
adhesion, possesses antithrombotic effects and preserves
shear-mediated nitric oxide production [8]. In addition,
endothelial glycosaminoglycans have been shown to be able
to bind sodium, thereby providing an intravascular compart-
ment for osmotically inactive sodium storage [9]. A damaged
ESL, which has been observed in conditions such as diabetes,
chronic kidney disease and end-stage renal disease, may there-
fore have signiﬁcant implications for sodium homeostasis and
BP regulation [10–13]. Consequently, ESL restoration may
decrease BP. Sulodexide, an orally available mixture of glycos-
aminoglycans, has been shown to restore the ESL in diabetic pa-
tients [14]. A meta-analysis that gathered BP data from eight
sulodexide trials, primarily investigating diabetic nephropathy
patients, has shown that sulodexide also decreases BP [15]. This
was seen particularly in hypertensive patients, who showed
placebo-subtracted BP reductions that were identical to those
found using current available antihypertensive drugs [15].
Considering the vasoprotective properties of the ESL and its
capacity to neutralize sodium-driven effects on volume status
by osmotic inactivation, this BP-lowering effect seems to be
attributed to ESL-restoring properties. Sulodexidemay therefore
be particularly effective in conditions that are characterized by
ESL damage.
Among diabetic patients, higher albuminuria levels are
associated with a marked reduction in ESL volume [13]. In
the present post hoc analysis of the randomized, double-blind,
placebo-controlled sulodexide microalbuminuria (Sun-MI-
CRO) and sulodexide macroalbuminuria (Sun-MACRO) tri-
als, we investigated whether the BP-lowering effect of
sulodexide is modiﬁed by the degree of albuminuria, in type
2 diabetic patients. Both trials were designed to investigate
the potential renoprotective effect of sulodexide but did not
show a reduction in albuminuria or in renal function decline
[16, 17]. The primary objective of the present analysis was to
compare the BP-lowering effects of sulodexide and placebo
among albuminuria groups.
Methods
Subjects and study design
The Sun-MICRO and Sun-MACRO trials investigated the
renoprotective effects of sulodexide 200 mg day–1 in subjects
with type 2 diabetes and maximal tolerable renin–angioten-
sin–aldosterone system inhibitor therapy [16–18]. The
Sun-MICRO trial included microalbuminuric subjects [a
urine albumin-to-creatinine ratio (UACR) of 35–200 mg g–1
in men and 45–200 mg g–1 in women] with serum creatinine
levels below 1.5 mg dl–1, whereas the Sun-MACRO trial
studied macroalbuminuric subjects (>0.9 g protein 24 h–1)
with renal impairment (serum creatinine in women
1.3–3.0 mg dl–1; in men 1.5–3.0 mg dl–1). Other inclusion
Table of Links
TARGETS
Enzymes [2] GPCRs [3]
ACE AT1-receptor
This Table lists key protein targets in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [1] and are permanently archived in the Concise Guide to PHARMA-
COLOGY 2015/16 [2, 3].
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and exclusion criteria were similar between both trials. Both
trials started simultaneously and were performed in the same
geographical areas and research centres [18]. As the rate of the
primary renal endpoint, a composite of a doubling of baseline
serum creatinine, development of end-stage renal disease, or
serum creatinine >6.0 mg dl–1, as well as proteinuria levels,
was identical in placebo and sulodexide groups in an interim
analysis of the Sun-MACRO trial, the study was terminated
early, after inclusion of 1248 subjects, with 1029 years of
follow-up. As a result of the early termination, the number
of subjects that had available BP measurements decreased
during the 6-month (n = 702), 9-month (n = 568) and
12-month (n = 426) Sun-MACRO follow-up visits. The
Sun-MICRO trial was fully completed and the number of
participants and BP recordings remained stable throughout
the study. All participants gave written informed consent
before enrolment in one of the studies. Both studies were
approved by the appropriate local research ethics committee
and performed in accordance with the Declaration of
Helsinki of the World Medical Association. All data were
processed anonymously.
Measurements
During both studies, at each visit, three seated BP measure-
ments were obtained 1 min apart, after at least 10 min of rest.
The mean BP of these measurements was used for analysis. BP
was recorded at 2-month intervals in the Sun-MICRO trial and
at 3-month intervals in the Sun-MACRO trial. The target BP in
both trials was <130/80 mmHg. We calculated the individual
BP changes from baseline to assess the effects of sulodexide
and placebo. As most antihypertensive treatments exert their
maximal BP-reducing effects after 6–8 weeks, we used BP
values from the ﬁrst follow-up visit to analyse whether UACR
modiﬁed the observed BP effects (i.e. after 2 months or
3 months). In both trials, albuminuria was determined as the
geometric mean of the ratio of urine albumin concentration
to urine creatinine concentration for three consecutive ﬁrst
morning voided urine samples collected before the study visit.
Considering that the sodium-binding potential of ESL
glycosaminoglycans might serve as an explanation for
sulodexide-associated BP changes, we analysed changes in
body weight to determine whether BP changes were related
to changes in extracellular volume. In addition, we analysed
plasma sodium concentrations during follow-up, and investi-
gated whether changes in plasma sodium concentrations or
body weight were associated with BP changes. Plasma sodium
concentration was measured only in the Sun-MACRO study.
Statistics
Data are presented as means with standard deviations, or
medians with interquartile ranges when skewed. We used
independent sample t-tests to compare BP reductions
between treatment groups. To analyse whether the degree of
albuminuria affected the BP effects of sulodexide, we used a
one-way analysis of covariance (ANCOVA), with treatment
group as the ﬁxed effect. The following patient characteristics
were assessed as possible effect modiﬁers: age, gender, base-
line systolic BP (SBP), diastolic BP (DBP), estimated glomeru-
lar ﬁltration rate (eGFR), body mass index (BMI) and
glycosylated haemoglobin (HbA1c). Baseline characteristics
that were signiﬁcantly associated with BP changes were
entered in an ANCOVA model, along with UACR, to investi-
gate whether these factors modiﬁed the BP response. For this
analysis, UACR values were log transformed. Effect modiﬁca-
tion was assessed by the interaction term ‘treatment*patient
characteristic’. To quantify the effects of albuminuria on the
BP effects of sulodexide, we plotted the estimated SBP effects
in a linear regression analysis and divided subjects in groups
with an UACR of <300 mg g–1, 300–1000 mg g–1 and
>1000 mg g–1.
To compare SBP, DBP, body weight and plasma sodium
changes following sulodexide and placebo treatment during
follow-up, we used a general linear model for repeated
measurements, with correction for baseline values. All statis-
tical analyses were performed using SPSS (Version 21.0, SPSS,
Inc., Chicago, IL, USA)
Results
Study population
BP measurements of 1056 and 843 subjects were available in
the Sun-MICRO and Sun-MACRO trial, respectively. The aver-
age baseline BP was 131/74 mmHg in the Sun-MICRO trial
and 138/73 mmHg in the Sun-MACRO trial. In comparison
to the Sun-MICRO trial, subjects included in the Sun-MACRO
trial had a lower eGFR and higher UACR at baseline (Table 1).
BP effects during follow-up
For the entire study population, placebo (1.4 ± 14.8 mmHg)
and sulodexide (0.3 ± 14.8 mmHg) resulted in identical SBP
changes (P = 0.10) after 2–3 months. In microalbuminuric
subjects, sulodexide did not change BP relative to placebo. Af-
ter 2 months, we observed comparable SBP changes in the
sulodexide (1.3 ± 11.3mmHg) and placebo (1.3 ± 11.7mmHg)
groups (placebo vs. sulodexide; P = 0.94). During the 26-week
follow-up period in which the subjects remained on the study
drug, SBP remained identical in both groups (Figure 1A). DBP
was also similar in both groups during follow-up. Interest-
ingly, sulodexide- and placebo-treated macroalbuminuric
subjects showed an opposite SBP response after 3 months:
SBP decreased in the sulodexide group by 0.9 ± 18.2 mmHg,
while it increased in the placebo group by 1.7 ± 17.9 mmHg
(placebo vs. sulodexide; P = 0.04). This SBP difference be-
tween sulodexide and placebo persisted after 6 months
(0.6 ± 17.8 mmHg vs. +2.3 ± 20.3 mmHg; P = 0.046). On av-
erage, SBP was 2.4 mmHg (P = 0.020) lower in the sulodexide
group during the ﬁrst year of treatment (Figure 1B). DBP did
not differ between the groups.
BP effect determinants
As albuminuria levels correlate with ESL status and may
therefore affect the BP response to sulodexide, we analysed
whether SBP changes were modiﬁed by baseline UACR. We
observed a signiﬁcant interaction between treatment and
baseline UACR (P = 0.001), indicating that the SBP effects of
sulodexide were modiﬁed by baseline BP (Table 2, Figure 2
A). Other potential characteristics, including SBP (P = 0.98
for interaction) and DBP (P = 0.93 for interaction), did not
show an interaction with treatment. The interaction between
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baseline UACR and treatment remained signiﬁcant after
adjustment for trial, baseline age, gender, eGFR, BMI and
HbA1c. Consequently, the largest SBP changes between the
placebo and sulodexide groups were observed in subjects
with the highest degree of albuminuria. Subjects with an
UACR >1000 mg g–1 who received sulodexide treatment
had a 4.6 mmHg [95% conﬁdence interval (CI) 3.6, 5.6;
P < 0.001] lower SBP than the placebo-treated subjects
(Figure 2B). In subjects with an UACR between 300 mg g–1
and 1000 mg g–1, SBP was, on average, 2.3 mmHg (95% CI:
0.9, 3.7; P = 0.001) lower in the sulodexide group
(P = 0.001). Microalbuminuric (<300 mg g–1) patients had
similar BP changes following sulodexide and placebo treat-
ment in this combined analysis of both studies (0.2 mmHg,
95% CI 0.5, 0.8; P = 0.60; Figure 2B).
As severe proteinuria may be a reﬂection of podocy-
topathy rather than additional damage to the endothelium
and ESL, we analysed the SBP changes in subgroups of pa-
tients with an UACR >1000 mg g–1. Although the difference
in SBP change remained signiﬁcant between placebo and
sulodexide in subgroups with an UACR of 1000–2000,
2000–3000 and >3000, the SBP changes were identical
among these subgroups for placebo (P = 0.38) and
sulodexide (P = 0.66). To test the robustness of our results,
Figure 1
Sulodexide reduced systolic blood pressure (SBP) in patients with macroalbuminuria. Estimated marginal means (standard error of the mean) of
SBP at baseline and after treatment with sulodexide and placebo in the sulodexide microalbuminuria (Sun-MICRO) (A) and sulodexide
macroalbuminuria (Sun-MACRO) (B) trials. In patients with microalbuminuria, SBP was identical in both groups (P = 0.88). In macroalbuminuric
patients, SBP was, on average, 2.4 mmHg lower [95% conﬁdence interval (CI) 0.4, 4.4; P = 0.020) in the sulodexide group (n = 204) when com-
pared with placebo (n = 198). We used a general linear model repeated measures test, with correction for baseline SBP for calculations
Table 1
Baseline characteristics of patients included in the post hoc analysis
Sun-MICRO Sun-MACRO









Male, n (%) 802 (75.9) 408 (76.7) 394 (75.2) 645 (76.3) 320 (74.2) 325 (78.5)
Age, years 62.2 (9.8) 62.3 (9.9) 62 (9.7) 62.9 (9.4) 63.4 (9.6) 62.3 (9.1)
SBP, mmHg 131.2 (11.8) 131.5 (11.8) 130.9 (11.8) 137.9 (14.3) 137.6 (14.6) 138.2 (14.0)
DBP, mmHg 73.6 (11.9) 73.4 (8.5) 73.8 (8.7) 73.2 (10.0) 73.0 (10.1) 73.4 (9.9)
BMI, kg m–2 32.1 (5.5) 31.9 (5.3) 32.3 (5.7) 32.8 (15.5) 31.7 (6.3) 34 (21.3)
eGFR, ml
min–1 1.73m–2
78.2 (22.4) 77.9 (22.7) 78.6 (22.1) 33.4 (9.6) 33.4 (9.7) 33.4 (9.5)
UACR, mg g–1
median (IQR)
96 (54–141) 95 (57–143) 97 (55–141) 1348 (648–2363) 1238 (606–2305) 1431 (704–2401)
HbA1c, % 7.6 (1.2) 7.5 (1.3) 7.6 (1.2) 8.0 (1.6) 7.9 (1.5) 8.1 (1.7)
BMI, bodymass index; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate; HbA1c, glycosylated haemoglobin; IQR, interquartile
range; SBP, systolic blood pressure; SD, standard deviation; Sun-MACRO, sulodexide macroalbuminuria; Sun-MICRO, sulodexide microalbuminuria;
UACR, urine albumin-to-creatinine ratio
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we analysed the Sun-MICRO and Sun-MACRO study sepa-
rately. This analysis demonstrated similar results, showing
that baseline UACR was not a determinant of SBP change
in Sun-MICRO, whereas a signiﬁcant interaction between
treatment and UACR was demonstrated in Sun-MACRO
(data not shown).
Plasma sodium and body weight
To explore whether sulodexide affected extracellular volume
regulation by osmotic inactivation of sodium, we analysed
plasma sodium concentration and body weight. Body weight
remained identical in sulodexide- and placebo-treated
subjects from Sun-MICRO during follow-up (P = 0.12). In
the Sun-MACRO study, plasma sodium concentrations
decreased in the placebo (0.3 ± 2.9 mmol l–1; P = 0.03) and
sulodexide (0.6 ± 3.0 mmol l–1; P < 0.001) groups to a simi-
lar extent after 3 months (P = 0.07). During the same period,
plasma glucose increased similarly after placebo
(1.0 ± 5.0 mmol l–1; P < 0.001) and sulodexide treatment
(0.7 ± 4.8 mmol l–1; P = 0.001). Similar to the results in
microalbuminuric subjects, body weight remained similar in
macroalbuminuric subjects during follow-up (P = 0.83).
Discussion
The present post hoc analysis demonstrated that the
BP-reducing potency of sulodexide depends on nephropathy
severity in subjects with type 2 diabetes and maximum toler-
ated renin–angiotensin-aldosterone system inhibitor ther-
apy. Relative to placebo treatment, the largest BP reductions
after sulodexide treatment were seen in subjects with the
highest degree of albuminuria (>1000 mg g–1), who showed
an additional 5 mmHg SBP reduction, despite a well-
controlled average BP at baseline. In microalbuminuric pa-
tients (UACR <300 mg g–1), sulodexide and placebo had sim-
ilar effects on SBP. Considering the high cardiovascular risk of
patients with severe diabetic nephropathy, it is likely that the
observed added BP-lowering effect of sulodexide translates
into a further reduction of cardiovascular risk.
A meta-analysis of randomized controlled trials that
investigated sulodexide has recently reported on the so-far
overlooked systemic BP effects of sulodexide [15]. In this
previous analysis, in which albuminuria could not be studied,
baseline BP was identiﬁed as themost important determinant
Table 2
Effect of urine albumin-to-creatinine ratio (UACR) on blood pres-
sure (BP) changes induced by sulodexide. The results of the anal-
ysis of covariance model that was used to investigate whether
baseline BP or UACR signiﬁcantly affected the systolic BP (SBP)
change that was observed after sulodexide or placebo treatment
(upper ﬁve rows with green background). To test whether base-
line BP or UACR modiﬁed the SBP change in placebo and
sulodexide groups differently, we tested for an interaction be-
tween the included patient characteristics and treatment (lower
three rows with white background). We observed a signiﬁcant in-
teraction for baseline UACR, but not for SBP or diastolic BP (DBP),
indicating that the BP effects of sulodexide are modiﬁed by base-
line UACR only. The represented values for treatment, trial, and
baseline UACR, SBP and DBP were calculated without taking into
account the effect of any interaction. The signiﬁcance of each in-
teraction was calculated separately
Figure 2
The blood pressure (BP)-lowering potential of sulodexide depends on albuminuria severity. (A) Regression lines and 95% conﬁdence intervals (CIs)
of the analysis of covariance (ANCOVA) demonstrating the signiﬁcant interaction (P = 0.001) between the baseline urine albumin-to-creatinine
ratio (UACR) and treatment arms (placebo vs. sulodexide). The regression line slopes of placebo (P< 0.001) and sulodexide (P< 0.001) were both
signiﬁcantly different from zero. (B) Quantitative analysis of the results of the ANCOVA, showing that subjects with an UACR>1000mg g–1 beneﬁt
most from sulodexide treatment in terms of BP (mean and 95% CI). Sulodexide resulted in a 2.0 mmHg (95% CI 2.6, 1.3) systolic BP (SBP)
reduction, while placebo increased SBP by 2.5 mmHg (95% CI 1.9, 3.3). In the group with an UACR between 300–1000 mg g–1, sulodexide de-
creased BP by 0.8 mmHg (95%CI1.8, 0.2) and placebo increased BP by 1.6 mmHg (95%CI 0.6, 2.5), while subjects with an UACR<300mg g–1
had an identical BP response (0.2 mmHg, 95% CI 0.5, 0.8; P = 0.60)
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of the observed BP response. In the current post hoc analysis,
we were able to analyse individual patient data, including
albuminuria. However, we could not reproduce this ﬁnding
using data from two large trials, in which average BP was well
controlled. Although baseline SBP was the most important
factor affecting SBP responses, we observed similar associa-
tions for placebo and sulodexide treatment groups. This indi-
cates that the association between baseline BP and the SBP
response is most likely caused by a regression-to-the-mean
phenomenon. As the inclusion BP was 150/90 mmHg and
160/100 mmHg in the Sun-MICRO and Sun-MACRO studies,
respectively, we were not able to draw any conclusions for BP
values above these levels. The most likely explanation for the
absent DBP response after sulodexide treatment is the low
baseline DBP.
Albuminuria is known to be a sign of kidney damage but
may also represent systemic vascular disease [19]. In this re-
spect, the ESL is an interesting vascular entity as it is involved
in both systemic vascular function and glomerular permeabil-
ity (i.e. albuminuria). In rats, for example, mesenteric and
vascular ESL thicknesses were both negatively correlated with
proteinuria [20]. This relationship has also been observed in
humans. In subjects with type 1 diabetes, the presence of
albuminuria was associated with a 75% reduction in systemic
ESL volume in comparison with nonalbuminuric controls
[13]. These studies suggest that albuminuria reﬂects systemic
ESL damage. As sulodexide is known to restore a damaged ESL
in diabetic patients, one may therefore expect that subjects
with a higher degree of albuminuria (i.e. a smaller systemic
ESL volume) may beneﬁt most from sulodexide therapy
[14]. This is in line with the results of the present post hoc
analysis, in which subjects with a higher degree of albumin-
uria, who may beneﬁt most from sulodexide in terms of ESL
restoration, showed the largest BP reductions. However, pro-
teinuria levels above 1 g are generally thought to be caused
by podocyte injury rather than by additional glomerular ESL
damage. As the BP-lowering effects of sulodexide may be
ascribed to ESL restoration, BP may not decrease any further
under conditions of severe proteinuria. Indeed, in our sub-
group analysis of subjects with UACR levels >1000 mg g–1,
we observed that SBP changes between placebo and
sulodexide remained signiﬁcant but did not increase further.
The BP-lowering potential of sulodexide may be
explained by several mechanisms, all of which can be attrib-
uted to an increased ESL volume. Firstly, the ESL is an impor-
tant mediator of shear-mediated nitric oxide production.
Secondly, ESL glycosaminoglycans have been shown to be
able to bind to and osmotically inactivate sodium, thereby
reducing the amount of osmotically active sodium, which
prevents water retention and a subsequent BP increase [9,
10, 21]. Both mechanisms may be responsible for the obser-
vation that the largest BP reductions after sulodexide treat-
ment were seen in subjects with the highest degree of
albuminuria. The observed reduction in BP was not character-
ized by any change in body weight, suggesting that extracel-
lular volume remained identical. However, plasma sodium
concentration decreased twice as much after sulodexide treat-
ment than after placebo, albeit not signiﬁcantly. Although
the 0.6 mmol l–1 decrease may seem marginal, it is similar to
reductions in plasma sodium concentration achieved with
long-termmodest salt reduction [22]. The absence of a weight
change, together with the decrease in plasma sodium concen-
tration that was seen alongside the BP reduction, indicates
that sulodexide-treated patients had less osmotically active
sodium per litre of body water. This suggests that sulodexide
is able to increase the capacity for non-osmotic sodium
storage. As these studies lacked data on extracellular volume
or total body water, these results should be interpreted
cautiously, and future studies should investigate whether
sulodexide interferes with sodium and volume homeostasis.
Besides albuminuria, plasma glucose has been reported
to affect ESL status [23]. In the present analysis, however,
we were not able to demonstrate an association between
plasma glucose and SBP response, either in micro- or
macroalbuminuric subjects. This may be explained by the
fact that a previous study observed differences in ESL status
while examining large intraindividual plasma glucose differ-
ences, whereas we assessed small interindividual differences
in the present study. In addition, eGFR has been shown to
affect ESL volume [11] but was not associated with the SBP
response in the present study. However, Padberg et al.
observed a similar association between both syndecan-1,
an ESL-shedding product, and proteinuria as well as between
syndecan-1 and eGFR [11]. As a decrease in eGFR and devel-
opment of albuminuria are both hallmarks of diabetic ne-
phropathy, it is difﬁcult to assess which factor may be
responsible for the reduction in ESL volume.
Similar to the previously mentioned meta-analysis, the
present post hoc analysis suggests that future studies should
take the systemic BP effects into account when analysing
the potential renoprotective effects of sulodexide [15]. In
both analyses, changes in BP and in UACR showed a signiﬁ-
cant correlation with a regression line that had a y-intercept
similar to zero.
The strength of the present study was the availability of
individual patient data from two large randomized placebo-
controlled trials [24]. To cover all ranges of albuminuria, we
pooled the data from the Sun-MICRO and Sun-MACRO trials
to investigate whether baseline albuminuria modiﬁed the
SBP responses. Although both trials were comparable with
regard to design, participating centres and measurements,
possible differences between studies could have induced bias.
However, we observed similar results in separate analyses of
the Sun-MICRO and Sun-MACRO trials. In addition, we
included trial as a covariate in the regression analysis, which
did not appear to have a signiﬁcant inﬂuence. A potential
limitation of the present analysis was the lack of 24 h BP data,
which may have been of additive value. Another potential
limitation was that patients were permitted to use adjunctive
antihypertensive agents. However, as both micro- and
macroalbuminuric subjects were allowed to take additional
agents, and both trials were double blinded, this effect was
not likely to inﬂuence our results signiﬁcantly. Due to the na-
ture of a post hoc analysis, we were not able to prove causality,
so these results should be interpreted cautiously.
Conclusion
The present post hoc analysis of the randomized, double-
blind, placebo-controlled Sun-MICRO and Sun-MACRO trials
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showed that the BP-reducing potency of sulodexide is modi-
ﬁed by the degree of albuminuria in type 2 diabetic patients.
Although the average subject was normotensive, sulodexide
reduced SBP by 5 mmHg in diabetic subjects with the highest
degree of albuminuria, indicating that sulodexide may help
to control BP in patients with severe diabetic nephropathy.
As the degree of albuminuria is generally believed to relate
to ESL damage, our ﬁndings indicate that ESL restoration
may represent a new target for BP treatment.
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